Moteur de recherche d’entreprises européennes
Financement de l’UE (5 980 435 €) : Efficacité et innocuité de l’IL-2 à faible dose (ld-IL-2) en tant qu’activateur de Treg pour le traitement anti-neuro-inflammatoire chez les patients atteints de … Hor05/05/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Efficacité et innocuité de l’IL-2 à faible dose (ld-IL-2) en tant qu’activateur de Treg pour le traitement anti-neuro-inflammatoire chez les patients atteints de sclérose latérale amyotrophique (SLA) nouvellement diagnostiqués
Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient selection, and outcome measures must be re-engineered to break the current impasse. Nerve cell death in ALS is associated with inflammation, which contributes to cell damage, and is a logical target for therapy. Although therapeutic attempts to modify this have failed so far, the discovery of regulatory T cells (Tregs) as key players in controlling inflammatory processes opens new possibilities since defective Treg function is important in ALS. In fact, Treg numbers and function predict rates of disease progression and survival. Low-dose interleukin-2 (ld IL-2) safely and specifically increases and activates Tregs in conditions such as type 1 diabetes, HBc-vasculitis and chronic graft-versus-host disease, so ld IL-2 has the potential to significantly improve survival and deliver a therapeutic breakthrough in ALS. We also integrate biomarkers for nerve cell damage into the trial design to provide proof of concept/mechanism. “Modifying Immune Response and OutComes in ALS” (MIROCALS) will test the hypothesis that ld IL-2-induced increases in Tregs result in decreased rates of nerve cell damage and that this effect can be detected early in the course of the disease using a range of blood and cerebrospinal fluid biomarkers. Our ambition is to develop a new therapy for ALS and through this novel trial design break the impasse in drug development of other disease-modifying agents in ALS. The impact will be to enhance quality of life and care for people with ALS, and provide a robust model for Industry to encourage investment in ALS and other neurodegenerative diseases.
| Association Genethon | 373 623 € |
| Centre Hospitalier Universitaire | 1 505 681 € |
| Goeteborgs Universitet | 140 500 € |
| Humanitas Mirasole S.p.A. | 450 000 € |
| Icon Clinical Research | 0,00 € |
| Icon Clinical Research (U.K.) Ltd. | 0,00 € |
| ICON CLINICAL RESEARCH GmbH | 0,00 € |
| Icon Clinical Research Ltd. | 659 105 € |
| Inserm Transfert SA | 421 000 € |
| King's College London | 490 790 € |
| Motor Neurone Disease Association | 0,00 € |
| Queen Mary University of London | 159 139 € |
| The University of Sheffield | 504 408 € |
| The University of Sussex | 856 330 € |
| WGK Consultancy Ltd. | 419 859 € |
https://cordis.europa.eu/project/id/633413
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
